Revolution Medicines, Inc. Common Stock
RVMD Real Time Price USDRecent trades of RVMD by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RVMD's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Methods of treating cancer with an mtor inhibitor Oct. 22, 2024
-
Patent Title: C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors Jul. 30, 2024
-
Patent Title: Compounds that participate in cooperative binding and uses thereof May. 21, 2024
-
Patent Title: Ras inhibitors Apr. 09, 2024
-
Patent Title: Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric shp2 inhibitors Aug. 29, 2023
-
Patent Title: Ras inhibitors Aug. 29, 2023
-
Patent Title: Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors Jul. 18, 2023
-
Patent Title: Ras inhibitors Jul. 04, 2023
-
Patent Title: C26-linked rapamycin analogs as mtor inhibitors Jun. 27, 2023
-
Patent Title: Polycyclic compounds as allosteric shp2 inhibitors Jun. 13, 2023
-
Patent Title: Pyridine compounds as allosteric shp2 inhibitors Jun. 13, 2023
-
Patent Title: 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors May. 30, 2023
-
Patent Title: Identifying new therapeutic agents May. 09, 2023
-
Patent Title: Polycyclic compounds as allosteric shp2 inhibitors Apr. 25, 2023
-
Patent Title: Ras inhibitors Mar. 21, 2023
-
Patent Title: Shp2 inhibitor compositions and methods for treating cancer Mar. 07, 2023
-
Patent Title: Ras inhibitors Jan. 31, 2023
-
Patent Title: C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors Jun. 21, 2022
-
Patent Title: Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a shp2 inhibitor Jan. 11, 2022
-
Patent Title: Bicyclic heteroaryl compounds and uses thereof Nov. 09, 2021
-
Patent Title: Compounds that participate in cooperative binding and uses thereof Jul. 13, 2021
-
Patent Title: Identifying new therapeutic agents Apr. 27, 2021
-
Patent Title: C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors Apr. 20, 2021
-
Patent Title: Methods and reagents for analyzing protein-protein interfaces Mar. 16, 2021
-
Patent Title: 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors Mar. 17, 2020
-
Patent Title: Compounds that participate in cooperative binding and uses thereof Jan. 14, 2020
-
Patent Title: Methods and reagents for analyzing protein-protein interfaces Nov. 05, 2019
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of RVMD in WallStreetBets Daily Discussion
Recent insights relating to RVMD
Recent picks made for RVMD stock on CNBC
ETFs with the largest estimated holdings in RVMD
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RVMD Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.